Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-8722

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy ; volume:12 ; number:1 ; day:12 ; month:3 ; year:2019 ; pages:1-11 ; date:12.2019
Journal of hematology & oncology ; 12, Heft 1 (12.3.2019), 1-11, 12.2019

Creator: Qin, Shuang
Li, Anping
Yi, Ming
Yu, Shengnan
Zhang, Mingsheng
Wu, Kongming

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13045-019-0718-5

URN: urn:nbn:de:101:1-2019040700594263174793

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.0015, 10:03 AM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Qin, Shuang
Li, Anping
Yi, Ming
Yu, Shengnan
Zhang, Mingsheng
Wu, Kongming
SpringerLink (Online service)

Other Objects (12)

3D tumor angiogenesis models: recent advances and challenges

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

Recent advances in pharmacological diversification of Src family kinase inhibitors

Editorial: Targeting bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Newer Tyrosine Kinase Inhibitors for CML

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Auto-thiophosphorylation activity of Src tyrosine kinase

3D tumor angiogenesis models: recent advances and challenges

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

Recent advances in pharmacological diversification of Src family kinase inhibitors

Editorial: Targeting bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Newer Tyrosine Kinase Inhibitors for CML

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Auto-thiophosphorylation activity of Src tyrosine kinase

3D tumor angiogenesis models: recent advances and challenges

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

Recent advances in pharmacological diversification of Src family kinase inhibitors

Editorial: Targeting bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Newer Tyrosine Kinase Inhibitors for CML

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Auto-thiophosphorylation activity of Src tyrosine kinase

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

3D tumor angiogenesis models: recent advances and challenges

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

Recent advances in pharmacological diversification of Src family kinase inhibitors

Editorial: Targeting bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Newer Tyrosine Kinase Inhibitors for CML

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Auto-thiophosphorylation activity of Src tyrosine kinase

3D tumor angiogenesis models: recent advances and challenges

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

Recent advances in pharmacological diversification of Src family kinase inhibitors

Editorial: Targeting bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Newer Tyrosine Kinase Inhibitors for CML

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Auto-thiophosphorylation activity of Src tyrosine kinase

3D tumor angiogenesis models: recent advances and challenges

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

Recent advances in pharmacological diversification of Src family kinase inhibitors

Editorial: Targeting bruton tyrosine kinase

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Newer Tyrosine Kinase Inhibitors for CML

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Auto-thiophosphorylation activity of Src tyrosine kinase

Related objects

Reset password